No Detail Found!

Do Alpha-Ketoanalogues slow down disease progression in non-dialysis dependent chronic kidney disease?

Author(s)
Bilal Saeed Department of Medicine, Combined Military Hospital (CMH),Peshawar,Pakistan
Khayam Department of Medicine, Combined Military Hospital (CMH),Peshawar,Pakistan
Zabihullah Afridi Department of Medicine, Combined Military Hospital (CMH),Peshawar,Pakistan
Muhammad Sana Ullah Department of Nephrology, Khyber Teaching Hospital, Peshawar, Pakistan
Wasif Anwar Department of Medicine, Combined Military Hospital (CMH),Peshawar,Pakistan
Abstract
Objective: To observe the effectiveness of keto-analogues in slowing down the disease progression in nondialysis dependent CKD patients. Study Design: Quasi-experimental study. Place and Duration of Study: The study was carried out at Nephrology Department of Combined Military Hospital (CMH), Peshawar, Pakistan from August 2022 to February 2023. Methods: Data was collected on 290 kidney disease improving global outcomes (KDIGO) stage 3 and 4 CKD patients through non-probability consecutive sampling technique. The cohort was divided into group A (Low protein diet) and B (ketodiet). Group A received low protein diet in addition to standard chronic disease treatment while Group B was labelled as keto-diet group which received ketoanalogues in addition to low protein diet and standard chronic kidney disease treatment. Baseline and six months eGFR was calculated and compared for both groups. SPSS version 23.00 was used for data analysis. The P value = 0.05 was considered significant. Results: 286 patients aged 51.84±18.127 were selected for our study. 188(65.73%) were males while females were 98 (34.26%). There were 142 (50.34%) and 144(50.34%) patients in group A and B respectively. Duration of CKD in group A and B was 6.45±2.55 and 6.49±1.75 years respectively. The means difference of eGFR in group A (low protein diet) at baseline and after six months was 3.64±1.09mL/ min/ 1.73m2 while that of group B was 1.48±0.41 mL/ min/ 1.73m2 (P-value <0.000). Conclusion: Ketoanalogues is an emerging therapy which slows down disease progression in non-dialysis dependent CKD patients. Although its use is recommended by some clinicians in CKD stage 3 and 4 non-dialysis dependent but still controversial.
Publication Details
Page(s) 427-431
Published Journal: Life and Science, Volume: 4, Issue: 4, Year: 2023

Request the full text from PASTIC

Keywords
Estimated Glomerular filtration rate, Chronic Kidney Disease, supplements, Protein Restricted Diet
0

Citations

0

Downloads

81

Views